« Back to Medicines list

Dioralyte Blackcurrant

Patient Information Leaflet Patient Information Leaflet last updated on medicines.ie: 17/05/21

files-icon(Click to Download)
Summary of Product Characteristics last updated on medicines.ie: 14/5/2021

Click on this link to Download PDF directly

SANOFI

SANOFI

Company Products

Medicine NameActive Ingredients
Medicine Name Adenocor Active Ingredients Adenosine
Medicine Name Amaryl 1mg Tablets Active Ingredients Glimepiride
Medicine Name Amaryl 3mg Tablets Active Ingredients Glimepiride
Medicine Name Anthisan Cream Active Ingredients Mepyramine Maleate
Medicine Name Apidra 100 units/ml solution for injection in a cartridge Active Ingredients Insulin Glulisine
Medicine Name Apidra 100 Units/ml solution for injection in a vial Active Ingredients Insulin Glulisine
Medicine Name Apidra SoloStar 100 units/ml solution for injection in a pre-filled pen Active Ingredients Insulin Glulisine
Medicine Name Aprovel 150mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 300mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Aprovel 75mg film-coated tablets Active Ingredients Irbesartan
Medicine Name Arava 10 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Arava 20 mg film-coated tablets Active Ingredients Leflunomide
Medicine Name Bisolvon Oral Solution Active Ingredients Bromhexine hydrochloride
Medicine Name Brolene 0.1%w/v Eye Drops Solution Active Ingredients Propamidine Isethionate
Medicine Name Brolene 0.15% w/w Eye Ointment Active Ingredients Dibromopropamidine Isethionate
Medicine Name Buscopan 10 mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Ampoules Active Ingredients hyoscine butylbromide
Medicine Name Buscopan Rx 10mg Coated Tablets Active Ingredients hyoscine butylbromide
Medicine Name Calcium Resonium Active Ingredients Calcium polystyrene sulfonate
Medicine Name Cerubidin 20mg Powder for Solution for Injection Active Ingredients daunorubicin hydrochloride
Medicine Name Cidomycin Paediatric 20mg/2ml Solution For Injection Active Ingredients Gentamicin sulfate
Medicine Name Claforan Powder for Solution for Injection 1g Active Ingredients Cefotaxime sodium
Medicine Name Claforan Powder for Solution for Injection 500mg Active Ingredients Cefotaxime sodium
Medicine Name Clexane 10,000 IU (100mg)/1ml Solution for Injection Active Ingredients Enoxaparin sodium
Medicine Name Clexane 2,000 IU (20 mg) /0.2 mL Solution for Injection Active Ingredients Enoxaparin sodium
1 - 0 of 166 items.Total: Infinity pages

When a pharmaceutical company changes any document, a new version is published on medicines.ie. For each version, we show the dates it was published on medicines.ie and the reasons for change.

Updated on 17 May 2021 PIL

Reasons for updating

  • Change to section 2 - use in children and adolescents
  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 14 May 2021 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Updated on 14 May 2021 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Updated on 28 April 2021 PIL

Reasons for updating

  • Change to section 3 - dose and frequency
  • Change to section 3 - use in children/adolescents
  • Change to section 3 - how to take/use
  • Change to section 3 - duration of treatment
  • Change to section 3 - overdose, missed or forgotten doses
  • Change to section 4 - possible side effects
  • Change to section 4 - how to report a side effect
  • Change to section 6 - date of revision

Updated on 28 April 2021 SPC

Reasons for updating

  • Change to section 2 - Qualitative and quantitative composition
  • Change to section 4.1 - Therapeutic indications
  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect
  • Change to section 10 - Date of revision of the text

Legal category: Supply through pharmacy only

Updated on 6 July 2020 PIL

Reasons for updating

  • XPIL Removed

Updated on 8 July 2019 SPC

Reasons for updating

  • File format updated to PDF

Legal category: Supply through pharmacy only

Updated on 26 March 2019 PIL

Reasons for updating

  • Change to section 2 - use in children and adolescents

Updated on 26 June 2018 SPC

Reasons for updating

  • Change to section 4.2 - Posology and method of administration
  • Change to section 4.3 - Contraindications
  • Change to section 4.4 - Special warnings and precautions for use
  • Change to section 4.6 - Pregnancy and lactation

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

 

Section 4.2          Posology and Method of Administration

Amended as follows:-

The contents of each sachet should be dissolved in 200ml (approximately 7 fluid ounces) of drinking water. 

Daily intake may be based on a volume of 150ml/kg body weight for infants up to the age of 24 months and 20-40 mgml/kg body weight for adults and children

Infants under 24 months              Use only under medical advice.

One to one and a half times the usual 24 hour feed volume.

Children over 24 months              One sachet after every loose motion

Adults including elderly One or two sachets after every loose motion.   .

More may be required initially to ensure early and full volume repletion.

Special population

No specific dose adjustment for the use of Dioralyte in elderly patients is recommended.

For patients with renal or hepatic impairment see section 4.4.

4.3 Contraindications

Amended as follows:-

Hypersensitivity to the active substances or to any of the excipients.

4.4 Special Warnings and Special Precautions for Use

Amended as follows:

Dioralyte should not be used for treatment in infants below the age of 24 months without medical supervision.

Dioralyte should not be used for self-treatment by patients with:

-              Chronic or persistent diarrhoea

-              Liver or kidney disease

-              Diabetes

-              On low potassium or sodium diets

-              Intestinal obstruction

The use of Dioralyte in patients with these conditions should be supervised by a doctor.

A weaker solution than recommended will not contain the optimal glucose and electrolyte concentration and a stronger solution than recommended may give rise to electrolyte imbalance.

4.6 Pregnancy and Lactation

Amended as follows:-

Medical supervision is recommended for use during pregnancy and lactation.

 

Updated on 26 June 2018 PIL

Reasons for updating

  • Change to section 1 - what the product is used for
  • Change to section 2 - what you need to know - warnings and precautions
  • Change to section 3 - how to take/use

Updated on 22 December 2016 SPC

Reasons for updating

  • New SPC for new product

Legal category: Supply through pharmacy only

Updated on 22 December 2016 SPC

Reasons for updating

  • Change to section 4.8 - Undesirable effects
  • Change to Section 4.8 – Undesirable effects - how to report a side effect

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

SmPC – Update to section 4.8 to include HPRA adverse event reporting details.

Updated on 19 December 2016 PIL

Reasons for updating

  • New PIL for new product

Updated on 19 December 2016 PIL

Reasons for updating

  • Change to section 2 - what you need to know - warnings and precautions

Updated on 18 June 2012 SPC

Reasons for updating

  • New individual SPC (was previously included in combined SPC)

Legal category: Supply through pharmacy only

Free text change information supplied by the pharmaceutical company

Section 6.3: Shelf life has been changed from 24 months to 36 months.
Section 6.4: Storage conditions have changed from 'Store in a cool dry place.' to 'Store below 25°C.  Store in the original package in order to protect from moisture.'
Section 7: Addition of 'Sanofi' as a trading style.

Updated on 14 June 2012 PIL

Reasons for updating

  • Change to storage instructions

Updated on 2 June 2010 PIL

Reasons for updating

  • Change due to user-testing of patient information

Updated on 10 November 2009 PIL

Reasons for updating

  • Improved electronic presentation

Updated on 13 October 2008 PIL

Reasons for updating

  • New PIL for medicines.ie